Availability of a small, cell-permeable molecule inhibitor of ENO1 such as ENOblock/AP-III-a4 [89] suggests that breast cancer patients with high levels of ENO1 mRNA can be potentially targeted for treatment. Here, ENO1 is linked to breast cancer.